Navigation Links
WNDM Signs $1.5 M Multiyear Regional Distribution Agreement
Date:4/12/2011

FORT WORTH, Texas, April 12, 2011 /PRNewswire/ -- Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions, today announced that the Company has signed a multi-year agreement with Omni Medical Products of McAllen, Texas to distribute CellerateRX® gel products in select states in the southwestern U.S.  To maintain the distributorship, the agreement calls for 1st year sales of at least $650,000 and additional sales each subsequent year.

According to Deborah Jenkins Hutchinson, President of Wound Management Technologies, "We are pleased to have Omni Medical Products distributing Wound Management's gel products in select states.  This agreement is part of our broader campaign to establish CellerateRX® as the standard of care in wound treatment."

Ron Mathis, Senior VP of Sales stated, "I am optimistic that as our sales increase we will continue to find broad distribution channels for the product. This new relationship along with our recent television campaigns should help to provide the exposure necessary to grow the company."

Scott Haire, WNDM CEO was quoted, "It is exciting to watch as our revenues continue to grow, partnerships like this with Omni along with the recent announcement of our Middle East orders are all very encouraging signs that we will achieve meeting our 2011 revenue projections."

For additional news and information concerning the CellerateRX® line of wound care products, please visit Wound Management Technology's newly re-launched product website www.CellerateRX.com.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage.  More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.

Follow us on: FACEBOOK | TWITTER | LINKEDIN

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com


'/>"/>
SOURCE Wound Management Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc.
2. Bacterin International Signs LOI to Acquire Assets of Robinson MedSurg LLC
3. MedPage Today Signs Exclusive Content & Advertising Deal with the American College of Cardiology for Coverage of More Than 20 Major Cardiology Meetings
4. MBL Signs Non-Exclusive License With Envoy Therapeutics for Access to RIP-Chip Technology
5. Spherix Signs Research Contract With a Leading Global Contract Research Organization to Investigate Role of D-tagatose in Lowering Triglycerides
6. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
7. Vet-Stem Signs License Agreement With Affiliate in Australia for Veterinary Stem Cells
8. ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin
9. Athera Signs Distribution Agreement in Scandinavia
10. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
11. Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...
(Date:12/8/2016)... Portland, Oregon (PRWEB) , ... December 08, 2016 ... ... modules and the FrontPanel SDK that provide essential device-to-computer interconnect using USB or ... do not require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module ...
(Date:12/8/2016)... ... 08, 2016 , ... KBioBox llc announced today the launch ... developed a sophisticated “3 click” gene dditing off target analysis program and a ... https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, pharmaceutical ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016  Soligenix, ... late-stage biopharmaceutical company focused on developing and commercializing ... an unmet medical need, announced today the long-term ... with SGX942 (dusquetide), a first-in-class Innate Defense Regulator ... in head and neck cancer patients undergoing chemoradiation ...
Breaking Biology Technology:
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
(Date:11/15/2016)... , Nov 15, 2016 Research and Markets ... Forecast to 2021" report to their offering. ... ... 16.18 Billion by 2021 from USD 6.21 Billion in 2016, growing ... Growth of the bioinformatics market is driven by the growing ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
Breaking Biology News(10 mins):